---
title: "Incyte Corp. Stock Underperforms Thursday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286469104.md"
description: "Incyte Corp. (INCY) shares fell 1.20% to $97.63 on Thursday, marking the third consecutive day of losses, despite a positive trading session for the overall market. The S&P 500 rose 0.77%, while Incyte's stock is now 13.06% below its 52-week high of $112.29. Competitors like Alnylam Pharmaceuticals saw a rise of 0.68%, while Bio-Techne and BioMarin experienced slight declines. Trading volume was below the 50-day average."
datetime: "2026-05-14T21:07:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286469104.md)
  - [en](https://longbridge.com/en/news/286469104.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286469104.md)
---

# Incyte Corp. Stock Underperforms Thursday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Incyte Corp. (INCY) slipped 1.20% to $97.63 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.77% to 7,501.24 and the Dow Jones Industrial Average rising 0.75% to 50,063.46.

This was the stock's third consecutive day of losses.

Incyte Corp. closed 13.06% below its 52-week high of $112.29, which the company achieved on January 7th.

The stock underperformed when compared to some of its competitors Thursday, as Alnylam Pharmaceuticals Inc. (ALNY) rose 0.68% to $293.45, Bio-Techne Corp. (TECH) fell 0.33% to $44.74, and BioMarin Pharmaceutical Inc. (BMRN) fell 0.58% to $53.24.

Trading volume (1.4 M) remained 152,848 below its 50-day average volume of 1.5 M.

Data source: Dow Jones Market Data, FactSet. Data compiled May 14, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-14-26 1707ET

### Related Stocks

- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [TECH.US](https://longbridge.com/en/quote/TECH.US.md)
- [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Incyte And Genesis Expand Molecular Ai Collaboration To Accelerate Drug Discovery](https://longbridge.com/en/news/287067847.md)
- [Incyte expands Genesis Molecular AI collaboration, pays USD 120 million upfront](https://longbridge.com/en/news/287060301.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)
- [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md)